Literature DB >> 12766668

Treatment of excessive bleeding in Jehovah's Witness patients after cardiac surgery with recombinant factor VIIa (NovoSeven).

Kenichi A Tanaka1, Amr A Waly, William A Cooper, Jerrold H Levy.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12766668     DOI： 10.1097/00000542-200306000-00034

Source DB:  PubMed          Journal:  Anesthesiology        ISSN： 0003-3022            Impact factor:   7.892


× No keyword cloud information.
  9 in total

Review 1.  Recombinant factor VIIa: a review on its clinical use.

Authors:  Massimo Franchini
Journal:  Int J Hematol       Date:  2006-02       Impact factor: 2.490

2.  Poly-N-acetylglucosamine fibers amplify the effectiveness of recombinant factor VIIA on clot formation in hemophilia B canine blood.

Authors:  Thomas H Fischer; Timothy C Nichols; Christopher M Scull; Carr J Smith; Marina Demcheva
Journal:  J Trauma       Date:  2011-08

3.  Preanesthetic Assessment of the Jehovah's Witness Patient.

Authors:  Eric S Lin; Alan D Kaye; Amir R Baluch
Journal:  Ochsner J       Date:  2012

Review 4.  [Perioperative management of Jehovah's Witness patients. Special consideration of religiously motivated refusal of allogeneic blood transfusion].

Authors:  O Habler; B Voss
Journal:  Anaesthesist       Date:  2010-04       Impact factor: 1.041

5.  The interaction of factor VIIa with rehydrated, lyophilized platelets.

Authors:  Thomas H Fischer; Alisa S Wolberg; Arthur P Bode; Timothy C Nichols
Journal:  Platelets       Date:  2008-05       Impact factor: 3.862

Review 6.  Mechanistic implications for the use and monitoring of recombinant activated factor VII in trauma.

Authors:  Anthony E Pusateri; Myung S Park
Journal:  Crit Care       Date:  2005-10-07       Impact factor: 9.097

Review 7.  Review of abdominal solid organ transplantation in Jehovah's Witness patients.

Authors:  Rodrigo S Figueiredo; Rohan G Thakkar; Paul R Ainley; Colin H Wilson
Journal:  World J Transplant       Date:  2019-09-26

8.  Use of activated recombinant factor VII for severe coagulopathy post ventricular assist device or orthotopic heart transplant.

Authors:  Manish J Gandhi; Richard A Pierce; Lini Zhang; Marc R Moon; George J Despotis; Nader Moazami
Journal:  J Cardiothorac Surg       Date:  2007-07-06       Impact factor: 1.637

Review 9.  Recombinant factor VIIa for uncontrollable bleeding in patients with extracorporeal membrane oxygenation: report on 15 cases and literature review.

Authors:  Xavier Repessé; Siu Ming Au; Nicolas Bréchot; Jean-Louis Trouillet; Pascal Leprince; Jean Chastre; Alain Combes; Charles-Edouard Luyt
Journal:  Crit Care       Date:  2013-03-25       Impact factor: 9.097
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.